General Information of Drug Transporter (DT)
DT ID	DTD0129 Transporter Info
Gene Name	SLC1A1
Protein Name	Excitatory amino acid transporter 3
Gene ID	6505
UniProt ID	P43005
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs301434
Site of GPD	chr9:4582082 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.3872/1939 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Rheumatoid Arthritis	Allele T is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele C.		[ 1]
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Allele T is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele C.		[ 1]
Selective serotonin reuptake inhibitors	N.A.	Obsessive-Compulsive Disorder	Correlated with the increased severity of pharmacological resistance in patients (compare with allele C)		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the CC genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the TT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genetic Polymorphism	rs301435
Site of GPD	chr9:4582843 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.3726/1866 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Rheumatoid Arthritis	Allele C is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele T.		[ 1]
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Allele C is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele T.		[ 1]
Selective serotonin reuptake inhibitors	N.A.	Obsessive-Compulsive Disorder	Correlated with the increased severity of pharmacological resistance in patients (compare with Allele T)		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the TT genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genetic Polymorphism	rs3087879
Site of GPD	chr9:4586808 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C
Minor Allele Frequency	C=0.2280/1142 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Rheumatoid Arthritis	Allele C is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele G.		[ 1]
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Allele C is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele G.		[ 1]
Selective serotonin reuptake inhibitors	N.A.	Obsessive-Compulsive Disorder	Correlated with the increased severity of pharmacological resistance in patients (compare with Allele G)		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the CG genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Selective Serotonin Reuptake Inhibitors	N.A.	Obsessive-compulsive Disorder	Patients with the GG genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.		[ 1]
Genetic Polymorphism	rs2228622
Site of GPD	chr9:4564432 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.6730/1331 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Clozapine	N.A.	Rheumatoid Arthritis	Allele A is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Olanzapine	N.A.	Rheumatoid Arthritis	Allele A is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Risperidone	N.A.	Rheumatoid Arthritis	Allele A is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Genetic Polymorphism	rs3780413
Site of GPD	chr9:4567353 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G
Minor Allele Frequency	C=0.4240/839 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Clozapine	N.A.	Rheumatoid Arthritis	Allele G is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Olanzapine	N.A.	Rheumatoid Arthritis	Allele G is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Risperidone	N.A.	Rheumatoid Arthritis	Allele G is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Genetic Polymorphism	rs3780412
Site of GPD	chr9:4572480 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.5420/1072 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Clozapine	N.A.	Rheumatoid Arthritis	Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Olanzapine	N.A.	Rheumatoid Arthritis	Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Risperidone	N.A.	Rheumatoid Arthritis	Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.		[ 2]
Genetic Polymorphism	rs10815019
Site of GPD	chr9:4547288 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.6550/1296 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Diarrhea	Allele A is not associated with likelihood of Diarrhea when treated with irinotecan in people with Neoplasms as compared to allele G.		[ 3]
References
1	Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive-compulsive disorder. Pharmacogenomics J. 2013 Oct;13(5):470-5.
2	Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry. 2009 Nov;66(11):1233-41.
3	Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect. PLoS One. 2014;9(8):e105160.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.